Cadence Pharmaceuticals Inc. (CADX)

[surf1944]

Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
PR NewswirePress Release: Cadence Pharmaceuticals, Inc. – Tue, Nov 22, 2011 7:49 PM EST

SAN DIEGO , Nov. 22, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX - News) today announced the closing of its previously announced public offering of 21,800,000 shares of its common stock, including 2,800,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering price of $3.75 per share. The net proceeds from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $77.4 million .

Deutsche Bank Securities Inc. acted as sole book-running manager, Leerink Swann LLC acted as co-lead manager and Cowen and Company, LLC acted as co-manager for the offering.

The securities described above were offered by Cadence pursuant to a shelf registration statement that had been previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311-3901, or by telephone at: [phone], or by email at: [e-mail]. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.